Renalytix Plc - ADR Stock News

Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9)) advanced to 6p, up 7%, alongside disclosures of a larger UBS holding and share purchases by chief executive James McCullough. The kidney diagnostics company reported UBS voting rights of 6.62%, up from 5.17% in the previous notification, in a filing released on Friday.

Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) jumped 19% to 5p on Tuesday as trading resumed following a fundraise that pulled in £10.5 million for the AIM-listed diagnostics firm. The company had paused trading in its shares at the start of September while it lined up new investment, including a placing with institutional backers and an offer allowing existing retail shareholders to b...

Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and - for the first time - measurable reduction in individual patient risk trajectories over 24 months NEW YORK, June 30, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnos...

Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) climbed 24% to 2.35p after the precision diagnostics company published two-year data showing its kidney disease test was linked to lasting improvements in patient health. The study of 2,470 patients with type 2 diabetes and early-stage chronic kidney disease was carried out across two US health systems, Mount Sinai in New York and Wake Fore...